How much revenue does Jiangsu Sihuan Bioengineering make?

Jiangsu Sihuan Bioengineering reported 344.38 million CNY in revenue for fiscal year 2025, up 69.2% from 203.52 million CNY in fiscal year 2024. In Q1 2026 revenue was 81.17 million CNY.

What companies are similar to Jiangsu Sihuan Bioengineering?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Beijing Bohui Innovation Biotechnology Group Co., Ltd. (300318.SZ), Harbin Medisan Pharmaceutical Co., Ltd. (002900.SZ), Hefei Lifeon Pharmaceutical Co., Ltd. (003020.SZ), Zhuhai Rundu Pharmaceutical Co., Ltd. (002923.SZ).

Jiangsu Sihuan Bioengineering Co., Ltd (000518.SZ) Stock

About Jiangsu Sihuan Bioengineering Co., Ltd

Jiangsu Sihuan Bioengineering Co., Ltd., together with its subsidiaries, engages in the production and sales of biopharmaceutical products in China and internationally. The company offers Delusen and New Delusen, a human interleukin-2 for injection are immunomodulators used for the biotherapy of tumors and treatment of patients with weakened immune function; Xinlisheng, a human granulocyte colony-...

At a glance

Jiangsu Sihuan Bioengineering reported revenue of 344.38 million CNY for fiscal year 2025, up 69.2% from fiscal year 2024, and net income of -37.09 million CNY. In Q1 2026 (the quarter ended March 31, 2026) revenue was 81.17 million CNY, up 85.1% from a year before.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.